1. Medtech Insight
  2. >>Device Area

Gleamer Charts Multi-Modality Future With FDA Nod And MRI Acquisitions

The French Start-up Is Laying Groundwork For A Full-Suite Diagnostic Platform Across X-Ray, CT And MRI.

 
• By Shubham Singh

ChestView, Gleamer’s newly FDA-cleared solution, is designed for chest X-ray interpretation and is the latest addition to its Gleamer Copilot suite. ChestView, which operates as a computer-aided detection system that can simultaneously detect multiple pathologies on images to support radiologists, is being rolled out in the US.

The FDA clearance expands Gleamer’s Copilot suite footprint in the US market.
Key Takeaways

· Gleamer CEO Allouche sees CADe-style annotation as critical to clinician trust and AI adoption in high-volume imaging tasks.

· Whole-body MRI remains off the table for now, with Gleamer focusing on enhancing existing care pathways.

· Predictive support, real-world evidence, and computing advances will shape AI’s clinical relevance in the next five years.

As radiologists contend with heavier caseloads and shrinking time to interpret images, artificial intelligence (AI) is emerging not just as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diagnostic Imaging

More from Medtech Insight

Ceryx Medical Amasses £11M To Develop Adaptive Cardiac Pacing Technology

 
• By Natasha Barrow

The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.